


BNP Paribas Funds Health Care Innovators K Capitalisation / LU2249613758 / A3EAVX / BNP PARIBAS AM (LU)

Last 10/30/2024 ¹	Region	Branch	Type of yield	Type
129.25 EUR	Worldwide	Sector Health / Pharma	reinvestment	Equity Fund



Risk key figures	
SRI	1 2 3 4 5 6 7
Mountain-View Funds Rating ²	EDA ³
▲▲▲▲▲	79

Yearly Performance	
2023	-0.45%

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	0.00%	Minimum investment	UNT 0
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Health / Pharma	Deposit fees	0.00%	UCITS / OGAW	Yes
Fund domicile	Luxembourg	Redemption charge	2.25%	Performance fee	0.00%
Tranch volume	(10/30/2024) EUR 48.70 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(10/30/2024) EUR 1,748.87 mill.	Dividends		Investment company	
Launch date	1/29/2021			BNP PARIBAS AM (LU)	
KESr report funds	No			10, rue Edward Steichen, 2540, Luxembourg	
Business year start	01.01.			Luxembourg	
Sustainability type	-			https://www.bnpparibas-am.com	
Fund manager	Jon Stephenson				

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	+0.22%	+3.17%	+12.00%	+23.99%	-	-	-	+10.96%
Performance p.a.	-	-	-	+23.92%	-	-	-	+5.70%
Sharpe ratio	-0.03	0.28	0.99	1.71	-	-	-	0.22
Volatility	9.92%	12.01%	11.80%	12.25%	0.00%	0.00%	0.00%	12.31%
Worst month	-	-5.83%	-5.83%	-5.83%	-5.83%	0.00%	0.00%	-5.83%
Best month	-	3.20%	6.27%	6.27%	6.27%	0.00%	0.00%	6.27%
Maximum loss	-2.13%	-6.66%	-6.66%	-6.66%	0.00%	0.00%	0.00%	-

Distribution permission
Austria, Germany, Switzerland, Czech Republic

¹ Important note on update status: The displayed date refers exclusively to the calculation of the NAV.
² The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

BNP Paribas Funds Health Care Innovators K Capitalisation / LU2249613758 / A3EAVX / BNP PARIBAS AM (LU)

Investment strategy


The Fund seeks to increase the value of its assets over the medium term by investing in shares issued worldwide by companies which innovate or benefit from healthcare innovation including but not limited to advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology in the healthcare field. Environmental, social and governance (ESG) criteria contribute to, but are not a determining factor in, the manager's decision making.

Investment goal


The Fund is actively managed and as such may invest in securities that are not included in the index which is MSCI World Health Care 10/40 (NR). The Benchmark is used for performance comparison only. The Fund is not benchmark constrained and its performance may deviate significantly from that of the benchmark.

Assessment Structure


Assets




Largest positions



Countries



Branches



Currencies

